Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. Its incidence is approximately 180,000

  • 11 views
  • 23 Jan, 2021
  • 1 location
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

newly diagnosed estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) metastatic breast cancer may be eligible.

stage iv breast cancer
erbb2
hormone therapy
locally advanced breast cancer
gonadotropin releasing hormone
  • 12 views
  • 20 Jul, 2021
  • 1 location
Leflunomide in Previously Treated Metastatic Triple Negative Cancers

Triple negative breast cancer (TNBC) represents about 15% of breast cancers and is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and HER-2 non

stage iv breast cancer
erbb2
cancer
progesterone receptor
triple negative breast cancer
  • 10 views
  • 23 Jan, 2021
  • 1 location
Amnion Bilayer and Stem Cell Combination Therapy on Thin Endometrium Infertile Patients

stained using IHC against -cadherin, estrogen receptor , progesterone receptor. Endometrial receptivity (HOXA10, LIF (early secretory) adhesion, VEGF, osteopontin (SPP1) to indicate the pinopodes will be

  • 0 views
  • 27 Jan, 2021
  • 1 location
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

This phase I/II trial studies the side effect and best dose of neratinib and to see how well it works with paclitaxel and with or without pertuzumab and trastuzumab before combination chemotherapy in treating patients with breast cancer that has spread to other places in the body (metastatic). Neratinib may …

cancer
carcinoma
probe
breast surgery
neutrophil count
  • 12 views
  • 28 Mar, 2021
  • 2 locations
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

This phase II trial studies how well pembrolizumab works in treating patients with stage IV inflammatory breast cancer or triple-negative breast cancer that has spread to other places in the body (metastatic) or has come back (recurrent), and who have achieved clinical response or stable disease to prior chemotherapy. Immunotherapy …

triple-negative breast cancer
cancer
neutrophil count
pleural effusion
biomarker analysis
  • 32 views
  • 26 Jan, 2021
  • 1 location
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

This randomized phase II trial studies how well carboplatin and paclitaxel with or without panitumumab work in treating patients with invasive triple negative breast cancer. Drugs used in the chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the …

cancer
carcinoma
neutrophil count
biomarker analysis
absolute neutrophil count
  • 0 views
  • 23 Jan, 2021
  • 2 locations
Pembrolizumab in Treating Patients With Hormone Receptor Positive Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

This phase II trial studies how well pembrolizumab works in treating patients with hormone receptor positive inflammatory breast cancer that has not spread to other parts of the body, who are receiving hormone therapy and did not achieve a pathological complete response to chemotherapy. Immunotherapy with monoclonal antibodies, such as …

cancer
carcinoma
neutrophil count
pembrolizumab
inflammatory breast cancer
  • 66 views
  • 28 Jan, 2021
  • 2 locations
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian Primary Peritoneal Fallopian Tube Endometrial or Triple Negative Breast Cancer

This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and gemcitabine hydrochloride in treating patients with folate receptor (FR) alpha-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple negative breast cancer that has come back. Mirvetuximab soravtansine is a monoclonal antibody, called mirvetuximab, linked to …

cancer
neutrophil count
doxorubicin
biomarker analysis
eribulin
  • 58 views
  • 27 Jan, 2021
  • 3 locations
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with pembrolizumab in treating patients with stage IV triple negative breast cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune …

cancer
neutrophil count
biomarker analysis
pembrolizumab
immunohistochemistry
  • 42 views
  • 05 Jun, 2021
  • 1 location